Overview

• Genomic diagnostics firm's Q4 2025 revenue rose 27% yr/yr

• Exome and genome test revenue grew 32% yr/yr

• Adjusted net income for Q4 2025 was $4.4 mln

Outlook

• GeneDx reaffirms 2026 revenue guidance of $540 to $555 mln

• Company expects 33-35% growth in exome and genome revenue for 2026

• GeneDx anticipates adjusted gross margin of at least 70% in 2026, and adjusted net income to be positive

Result Drivers

• EXOME AND GENOME TESTS - Revenue from exome and genome tests increased 32% yr/yr, driven by higher test volumes

• GROSS MARGIN IMPROVEMENT - Adjusted gross margin improved to 71%, reflecting efficient cost management

• MARKET EXPANSION - Expansion into general pediatrics and prenatal diagnostics contributed to revenue growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Adjusted Net Income		$4.40 mln
Q4 Net Income		-$17.70 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy"

• Wall Street's median 12-month price target for GeneDx Holdings Corp is $170.00, about 107.2% above its February 20 closing price of $82.06

• The stock recently traded at 122 times the next 12-month earnings vs. a P/E of 125 three months ago

Press Release: ID:nBw2rxdF8a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.